Submit Deal

Announced

22 Apr 2014

Valeant Pharmaceuticals and Pershing Square failed to acquire Allergan for $52bn.

Synopsis

Valeant Pharmaceuticals, a global pharmaceutical company, and Pershing Square Capital Management, an investment advisory firm, failed to acquire Allergan, an American, Irish-domiciled pharmaceutical company, for $52bn.

Principals

target

Allergan

bidder

Valeant Pharmaceuticals

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (12)

cary hyden

Partner at Latham & Watkins

Lawyer

target

Deals

£ 31.14 B

Total Value

paul d. tosetti

Partner at Latham & Watkins

Lawyer

target

Deals

£ 35.75 B

Total Value

donald bussard

‎Partner at Richards Layton and Finger

Lawyer

target

Deal

£ 30.95 B

Total Value

mark j. gentile

Director at Richards Layton and Finger

Lawyer

target

Deals

£ 87.73 B

Total Value

john mark zeberkiewicz

Director at Richards Layton and Finger

Lawyer

target

Deal

£ 30.95 B

Total Value

paul donofrio

Vice Chair at Bank of America

Financial Advisor

target

Deal

£ 30.95 B

Total Value

steven baronoff

Chairman at Bank of America

Financial Advisor

target

Deals

£ 90.10 B

Total Value

albert hwan

Banker at Bank of America

Financial Advisor

target

Deal

£ 30.95 B

Total Value

joseph sala

Partner at Joele Frank

PR Consultant

target

Deals

£ 299.17 B

Total Value

james katzman

‎Partner at Goldman Sachs

Financial Advisor

target

Deal

£ 30.95 B

Total Value

chuck adams

Partner and Managing Director at Goldman Sachs

Financial Advisor

target

Deals

£ 36.96 B

Total Value

scott bisang

Managing Director at Joele Frank

PR Consultant

target

Deals

£ 344.37 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy